Avtor/Urednik		Blinc, A; Kozak, M; Šabovič, M; Božič, M; Stegnar, M; Poredoš, P; Kravos, A; Barbič-Žagar, B; Pohar-Perme, M; Stare, J
Naslov		Prevention of ischemic events in patients with peripheral arterial disease design, baseline characteristics and 2-year results an observational study
Tip		članek
Vir		Int Angiol
Vol. in št.		Letnik 30, št. 6
Leto izdaje		2011
Obseg		str. 555-66
Jezik		eng
Abstrakt		Aim: Peripheral arterial disease (PAD) is associated with frequent cardiovascular ischemic events. We followed the survival of PAD patients and tested whether PAD remains an adverse prognostic indicator in spite of treatment according to the current European guidelines on cardiovascular disease prevention. Methods: Eight hundred eleven patients with PAD and 778 control subjects, aged 65 (SD 9) years at inclusion, with a male/female ratio of 3/2 were treated according to the European guidelines on cardiovascular disease prevention and evaluated yearly for occurrence of death, non-fatal acute coronary syndrome, stroke or critical limb ischemia (major events) and revascularization procedures (minor events). At baseline, classical risk factors were significantly more prevalent in the PAD group and protective cardiovascular medication was prescribed to patients with PAD more frequently than to control subjects. Results: In the PAD group, the 2-year Kaplan-Meier survival estimate was 96.7% (CI 95.4-97.9) vs. 98.2% (CI 97.2-99.1) in the control group, P=0.059. The groups differed in the 2-year major event-free survival: 93.5% (CI 92.7-95.3) in PAD vs. 97.1% (CI 95.9-98.4) in controls, P<0.017, as well as in event-free survival: 79.9% (CI 77.1-82.9) in PAD vs.96.4% (CI 95.0-97.9) in controls, P<0.001. Conclusion: Patients with PAD had a borderline higher risk of all-cause death and a significantly higher risk of major and minor non-fatal cardiovascular events compared to control subjects. However, treatment according to the European guidelines on cardiovascular disease prevention resulted in encouragingly low absolute mortality and morbidity. (ClinicalTrials.gov number NCT00761969.).
Deskriptorji		PERIPHERAL VASCULAR DISEASES ARTERIAL OCCLUSIVE DISEASES CARDIOVASCULAR DISEASES CORONARY DISEASE MYOCARDIAL INFARCTION LEG ISCHEMIA MYOCARDIAL REVASCULARIZATION BLOOD PRESSURE PRACTICE GUIDELINES